Federica FERRI

Dr. Federica FERRI


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2009 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
FFFederica FERRI
Federica FERRI
HBHaniaa Bouzinba-Segard
Haniaa Bouzinba-Segard
GVGuillaume Velasco
Guillaume Velasco
Florent HubéFlorent Hubé
Florent Hubé
CFClaire Francastel
Claire Francastel
Non-coding RNAs are emerging as key players in many fundamental biological processes, including specification of higher-order chromatin structure. We examined the implication of RNA transcribed from mouse centromeric minor satellite repeats in the formation and function of centromere-associated complexes. Here we show that the levels of minor satellite RNA vary during cell-cycle progression, peaking in G2/M phase, concomitant with accumulation of proteins of the chromosomal passenger complex near the centromere. Consistent with this, we describe that murine minor satellite RNA are components of CENP-A-associated centromeric fractions and associate with proteins of the chromosomal passenger complex Aurora B and Survivin at the onset of mitosis. Interactions of endogenous Aurora B with CENP-A and Survivin are sensitive to RNaseA. Likewise, the kinase activity of Aurora B requires an RNA component. More importantly, Aurora B kinase activity can be potentiated by minor satellite RNA. In addition, decreased Aurora B activity after RNA depletion can be specifically rescued by restitution of these transcripts. Together, our data provide new functional evidence for minor satellite transcripts as key partners and regulators of the mitotic kinase Aurora B.

20 March 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
DGDenise Gay
Denise Gay
GGGiulia Ghinatti
Giulia Ghinatti
CGChristian F. Guerrero-Juarez
Christian F. Guerrero-Juarez
RFRubén A. Ferrer
Rubén A. Ferrer
FFFederica FERRI
Federica FERRI
PRPaul-Henri Romeo
Paul-Henri Romeo
Macrophages, renowned for clearance of debris and bacteria in the wound, can also uptake signaling inhibitors to promote fibrosis.

16 October 2007 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
SSSerafina Salvati
Serafina Salvati
FNFrancesco Natali
Francesco Natali
LALucilla Attorri
Lucilla Attorri
RBRita Di Benedetto
Rita Di Benedetto
FLFabiana Leonardi
Fabiana Leonardi
LVLuigi Vitelli
Luigi Vitelli

1 September 2017 in Cell Reports
Verified
Journal Article
Open access
SRSarah Rodrigues-Moreira
Sarah Rodrigues-Moreira
Stéphanie G. MorenoStéphanie G. Moreno
Stéphanie G. Moreno
GGGiulia Ghinatti
Giulia Ghinatti
DLDaniel Lewandowski
Daniel Lewandowski
FHFrançoise Hoffschir
Françoise Hoffschir
PRPaul-Henri Romeo
Paul-Henri Romeo
Despite numerous observations linking protracted exposure to low-dose (LD) radiation and leukemia occurrence, the effects of LD irradiation on hematopoietic stem cells (HSCs) remain poorly documented. Here, we show that adult HSCs are hypersensitive to LD irradiation. This hyper-radiosensitivity is dependent on an immediate increase in the levels of reactive oxygen species (ROS) that also promotes autophagy and activation of the Keap1/Nrf2 antioxidant pathway. Nrf2 activation initially protects HSCs from the detrimental effects of ROS, but protection is transient, and increased ROS levels return, promoting a long-term decrease in HSC self-renewal. In vivo, LD total body irradiation (TBI) does not decrease HSC numbers unless the HSC microenvironment is altered by an inflammatory insult. Paradoxically, such an insult, in the form of granulocyte colony-stimulating factor (G-CSF) preconditioning, followed by LD-TBI facilitates efficient bone marrow transplantation without myeloablation. Thus, LD irradiation has long-term detrimental effects on HSCs that may result in hematological malignancies, but LD-TBI may open avenues to facilitate autologous bone marrow transplantation.

1 April 2011 in Cell Stem Cell
Verified
Journal Article
Closed access
SKSophie Kusy
Sophie Kusy
NGNathalie Gault
Nathalie Gault
FFFederica FERRI
Federica FERRI
DLDaniel Lewandowski
Daniel Lewandowski
VBVilma Barroca
Vilma Barroca
PRPaul-Henri Romeo
Paul-Henri Romeo

20 September 2010 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SKSophie Kusy
Sophie Kusy
BGBastien Gerby
Bastien Gerby
NGNicolas Goardon
Nicolas Goardon
NGNathalie Gault
Nathalie Gault
FFFederica FERRI
Federica FERRI
PRPaul-Henri Roméo
Paul-Henri Roméo
TAL1 (also known as SCL) is expressed in >40% of human T cell acute lymphoblastic leukemias (T-ALLs). TAL1 encodes a basic helix-loop-helix transcription factor that can interfere with the transcriptional activity of E2A and HEB during T cell leukemogenesis; however, the oncogenic pathways directly activated by TAL1 are not characterized. In this study, we show that, in human TAL1–expressing T-ALL cell lines, TAL1 directly activates NKX3.1, a tumor suppressor gene required for prostate stem cell maintenance. In human T-ALL cell lines, NKX3.1 gene activation is mediated by a TAL1–LMO–Ldb1 complex that is recruited by GATA-3 bound to an NKX3.1 gene promoter regulatory sequence. TAL1-induced NKX3.1 activation is associated with suppression of HP1-α (heterochromatin protein 1 α) binding and opening of chromatin on the NKX3.1 gene promoter. NKX3.1 is necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown cells, and directly regulates miR-17-92. In primary human TAL1-expressing leukemic cells, the NKX3.1 gene is expressed independently of the Notch pathway, and its inactivation impairs proliferation. Finally, TAL1 or NKX3.1 knockdown abrogates the ability of human T-ALL cells to efficiently induce leukemia development in mice. These results suggest that tumor suppressor or oncogenic activity of NKX3.1 depends on tissue expression.